PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas
David S.P. Tan(National University of Singapore), Jorge S. Reis‐Filho(AstraZeneca (France)), W. Glenn McCluggage(Belfast Health and Social Care Trust), Marketa Zvelebil(Institute of Cancer Research), Hani Gabra(Royal Children's Hospital), Adam J.W. Paige(Hammersmith Hospital), Sydonia Rayter(Breast Cancer Research Foundation), Rachael Natrajan(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Caterina Marchiò(Candiolo Cancer Institute), Charles Jameson(Royal London Hospital), Mona El‐Bahrawy(Al-Azhar University), Narinder Tamber(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), Dana Faratian(Western General Hospital), Kay Savage(Institute of Cancer Research), A. Wynn Williams(University of Edinburgh), Christopher J. Lord(Institute of Cancer Research), Kerry Fenwick(Institute of Cancer Research), Felipe C. Geyer(Institute of Cancer Research), Stanley B. Kaye(Royal Marsden Hospital), Radost Vatcheva(Institute of Cancer Research), Maryou B. Lambros(Institute of Cancer Research), Tim Dexter(Institute of Cancer Research), Martin Gore(Imperial College London), Qiong Gao(Zunyi Medical University), Ashley Graham(University of Edinburgh), Suzanne Parry(Institute of Cancer Research)
Cited by 166
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k